Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy

Despite recent advances in multimodality therapy for glioblastoma (GB) incorporating surgery, radiotherapy, chemotherapy and targeted therapy, the overall prognosis remains poor. One of the interesting targets for GB therapy is the histone deacetylase family (HDAC). Due to their pleiotropic effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Everix, Liesbeth, Seane, Elsie Neo, Ebenhan, Thomas, Goethals, Ingeborg, Bolcaen, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967489/
https://www.ncbi.nlm.nih.gov/pubmed/37259375
http://dx.doi.org/10.3390/ph16020227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967489/
https://www.ncbi.nlm.nih.gov/pubmed/37259375
http://dx.doi.org/10.3390/ph16020227

Ejemplares similares